Attgeno appoints Björn Westberg as CFO

Attgeno appoints Björn Westberg as CFO

Jul 08, 2021 05:00 UTC

Attgeno AB announces today that Björn Westberg has been appointed CFO
and member of the management team at Attgeno. Björn most recently comes
from a role as CFO at Enea AB (publ).

Björn has extensive experience in the Life Science sector, where he has been
active for 24 years in both small biotech and global pharmaceutical
companies. In his previous roles as CFO, Björn has had four assignments in
Nasdaq-listed companies, including Recipharm and Bonesupport, and has
also led projects for listing on Nasdaq Stockholm. Björn’s responsibilities in
previous roles include finance, financing, investor relations, legal affairs,
strategy development, HR and IT.

I am very proud and happy to have been able to tie Björn to Attgeno. Through
his solid background and international experience in Life Science, Attgeno
receives an important contribution to further development into a successful
pharmaceutical company. The Board and I both look forward to the continued
work with Björn, which includes developing the company so that Attgeno’s
organization meets the requirements for listed companies, as a public listing is an
alternative that may be relevant in the upcoming years.”, says Per Agvald,
Attgeno’s co-founder and CEO.

Björn Westberg will take up the role of CFO in Attgeno in September 2021.

For further information, please contact
Per Agvald (MD, PhD), CEO
Telephone: +46 706 457 827
E-mail: per.agvald@attgeno.com

Christofer Adding (MD, PhD), CMO
Telephone: +46 707 886 766
E-mail: christofer.adding@attgeno.com

About Attgeno
Attgeno AB is a privately held Swedish biotech company devoted to
development and commercialization of innovative and effective nitric oxidedonating drugs.

Its leading drug candidate Supernitro (PDNO) is currently in
early (phase I/IIa) clinical development. For further information, please visit

www.attgeno.com.

About Supernitro (PDNO)
Supernitro is administered as an intravenous infusion, which upon entry into
the blood, has an ultra-short half-life rapidly releasing its active moiety nitricoxide (NO). As a result, the majority of its NO is released just through the short passage through the lung blood circulation where it reacts with the
blood vessels and causes them to dilate. The dilation reduces the resistance
for the blood flow through the lungs generated by the pumping of the right
heart, and thereby the lung blood pressure is decreased. With decreased
pressure to work against the right heart is alleviated. By the donation of NO
in the lungs, Supernitro replaces the decrease in NO production that is a
well-known consequence of different diseases leading to increased risk for
acute pulmonary hypertension.

About acute pulmonary hypertension
Acute pulmonary hypertension, due to acute elicited constriction of the
vessels in the lung blood circulation, is a feared complication to major
surgery, especially heart surgery, lung emboli and severe infections e.g.,
Covid-19. In acute pulmonary hypertension, constriction of blood vessels
within the lung causes increased resistance in the lung blood vessels with a
risk that the heart’s right ventricle does not have the capacity to sufficiently
pump the blood through the lungs. In severe cases, the consequence is right
heart failure and a drop in systemic blood pressure threatening blood flow to
vital organs such as the brain, liver, kidneys and the heart itself – which can
lead to a rapid death.

About Attgeno
Attgeno AB is a privately held Swedish biotech company devoted to
development and commercialization of innovative and effective nitric oxide donating drugs. Its leading drug candidate Supernitro (PDNO) is currently in early (phase I/IIa) clinical development.

For further information, please visit

www.attgeno.com.

 

Leave a Reply

Your email address will not be published. Required fields are marked *